Adverse effects of drugs on small intestine and colon

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 2, 2010, Pages 133-141

  Zeino, Zeino ^a   Sisson, Guy ^a   Bjarnason, Ingvar ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Colitis; Drug toxicity; Drug induced damage; Large intestine; Small intestine

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALBUMIN; ANTACID AGENT; ANTHRAQUINONE DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BEVACIZUMAB; CISPLATIN; FLUOROPYRIMIDINE; IRINOTECAN; IRON; LACTULOSE; LOPERAMIDE; MACROGOL; METHOTREXATE; METRONIDAZOLE; MISOPROSTOL; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; POTASSIUM; SALAZOSULFAPYRIDINE; SUNITINIB; TETRACYCLINE; TETRAHYDROLIPSTATIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ANGIOGRAPHY; ARTERY THROMBOSIS; ARTICLE; ATONIC COLON; BLEEDING; BLOOD TRANSFUSION; BREAST CANCER; CAPSULE ENDOSCOPY; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; COLITIS; COLON CANCER; COLON DISEASE; COLON RESECTION; COLORECTAL CANCER; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIVERTICULITIS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENTEROCOLITIS; ENTEROPATHY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE RESECTION; IRON DEFICIENCY ANEMIA; KIDNEY CARCINOMA; LACTASE DEFICIENCY; LOW DRUG DOSE; MALABSORPTION; MELANOSIS; MELENA; METASTASIS; MUCOSA INFLAMMATION; MUCOSAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NUTRITIONAL DEFICIENCY; OBESITY; PERFORATION; PHARMACOLOGICAL PARAMETERS; PROTEIN DEPLETION; PSEUDOMEMBRANOUS COLITIS; RECTUM HEMORRHAGE; SIDE EFFECT; SMALL INTESTINE DISEASE; SMALL INTESTINE OBSTRUCTION; SUSTAINED DRUG RELEASE; VASOCONSTRICTION; VEIN THROMBOSIS; VOMITING;

COLON; COLONIC DISEASES; DRUG THERAPY; HUMANS; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINE, SMALL; RISK FACTORS;

EID: 77749341361     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2010.02.008     Document Type: Article

References (59)

1. Geboes K., Hertogh G.D., and Ectors N. Drug-induced pathology in the large intestine. Curr Diagn Pathol 12 (2006) 239-247
2. Bjarnason I., Hayllar J., Macpherson A.J., et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104 (1993) 1832-1847
3. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
4. Allison M.C., Howatson A.G., Torrance C.J., et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 327 (1992) 749-754
5. Bjarnason I., Zanelli G., Smethurst P., et al. Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures. Gastroenterology 94 (1988) 1070-1074
6. Maiden L., Thjodleifsson B., Seigal A., et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol (2007) 1040-1045
7. Endo H., Hosono K., Inamori M., et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 44 (2009) 544-549
8. Carson J., Notis W.M., and Orris E.S. Colonic ulceration and bleeding during diclofenac therapy. N Engl J Med 323 (1990) 135
9. Halter F., Weber B., Huber T., et al. Diaphragm disease of the ascending colon associated with sustained release diclofenac. J Clin Gastroenterol 16 (1993) 74-80
10. Huber T., Ruchti C., and Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology 100 (1992) 1119-1122
11. Sigthorsson G., Tibble J., Hayllar J., et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 43 (1998) 506-511
12. Hawkey C.J. COX-2 inhibitors. Lancet 353 (1999) 301-314
13. Vane J.R. Towards a better aspirin. Nature 367 (1994) 215-216
14. Vane J.R. NSAIDs, COX-2 inhibitors, and the gut. Lancet 346 (1995) 1105-1106
15. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
16. Lichtenberger L.M., Romero J.J., and Dial E.J. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol (2007) 913-919
17. Lichtenberger L.M., Wang Z.-M., Romero J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1 (1995) 154-158
18. Mahmud T., Rafi S.S., Scott D.L., et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 39 (1996) 1998-2003
19. Wallace J.L., McKnight W., Reuter B.K., et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
20. Wallace J.L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15 (2001) 691-703
21. Maiden L., Thjodleifsson B., Theodors A., et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128 (2005) 1172-1178
22. Bjarnason I., Hayllar J., Smethurst P., et al. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 33 (1992) 1204-1208
23. Hayllar J., Price A.B., Smith T., et al. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: effect of sulphasalazine and other disease modifying drugs. Arthritis Rheum 37 (1994) 1146-1150
24. Bjarnason I., Hayllar J., Somasundaram S., et al. Misoprostol in the treatment of NSAID-induced enteropathy: a double blind, placebo-controlled, parallel group study. Gastroenterology 104 (1993) A669
25. Bjarnason I., Zanelli G., Prouse P., et al. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet 2 (1987) 711-714
26. Armstrong C.P., and Blower A.L. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulcer disease. Gut 28 (1987) 527-532
27. Campbell K., and Steele R.J.C. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case control study. Br J Surg 78 (1991) 190-191
28. Corder A. Steroids, non-steroidal anti-inflammatory drugs and serious complications of diverticular disease. Br Med J 295 (1987) 1238
29. Coutrot S., Roland D., Barbier J., et al. Acute perforation of colonic diverticula associated with short term indomethacin. Lancet 2 (1978) 1055-1056
30. Cornish J.A., Tan E., Simillis C., et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 103 (2008) 2394-2400
31. Godet P.G., May G.R., and Sutherland L.R. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 37 (1995) 668-673
32. Behrens R., Devereaux M., Hazleman B., et al. Investigation of auranofin-induced diarrhoea. Gut 27 (1986) 59-65
33. Tallón Aguilar L., Casado Maestre M.D., López Bernal F., et al. Perforation of hollow viscera associated with cocaine use. Gastroenterol Hepatol 31 (2008) 624
34. Trinca K.D., DeGennaro V.A., Spector S., et al. Crack cecum. J Am Coll Surg 207 (2008) 612
35. Ellis C.N., and McAlexander W.W. Enterocolitis associated with cocaine use. Dis Colon Rectum 48 (2005) 2313-1216
36. Marteau P., Flourié B., Froguel E., et al. Proctitis following the prolonged use of dextropropoxyphene and paracetamol suppositories: the risk persists despite change of excipient. Gastroenterol Clin Biol 14 (1990) 102-103
37. Wörmann B., Höchter W., Seib H.J., et al. Ergotamine-induced colitis. Endoscopy 17 (1985) 165-166
38. Vincens M., Ganansia R., du Puy-Montbrun T., et al. Necrotizing anorectitis and proctitis after long term utilization of a dextropropoxyphene and paracetamol association in suppositories, 7 cases. Therapie 37 (1982) 321-326
39. Lloyd-Still J.D., Beno D.W., and Kimura R.M. Cystic fibrosis colonopathy. Curr Gastroenterol Rep 1 (1999) 231-237
40. Spada C., Riccioni M.E., Marchese M., et al. Isotretinoin-associated pan-enteritis. J Clin Gastroenterol 42 (2008) 923-925
41. Bjarnason I., Takeuchi K., Bjarnason A., et al. The G.U.T. of gut. Scand J Gastroenterol 39 (2004) 807-815
42. Hey H.S., chmedes A., Nielsen A.A., et al. Effects of five different alcoholic drinks on patients with Crohn's disease. Scand J Gastroenterol 42 (2007) 968-972
43. Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 651-659
44. Cheng J., Vemula N., and Gendler S. Small bowel obstruction caused by intramural hemorrhage secondary to anticoagulant therapy. Acta Gastroenterol Belg 71 (2008) 342-344
45. Petrelli N., Herrera L., Rustum Y., et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5 (1987) 1559-1565
46. Leichman C.G., Fleming T.R., Muggia F.M., et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13 (1995) 1303-1311
47. Abigerges D., Chabot G.G., Armand J.P., et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13 (1995) 210-221
48. Saliba F., Hagipantelli R., Misset J.L., et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16 (1998) 2745-2751
49. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
50. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
51. Messersmith W.A., Laheru D.A., Senzer N.N., et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10 (2004) 6522-6527
52. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24 2 (2006) 656-656
53. Cascinu S., Fedeli A., Fedeli S.L., et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 11 (1993) 148-151
54. Zidan J., Haim N., Beny A., et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 12 (2001) 227-229
55. Sharma R.K. Vincristine and gastrointestinal transit. Gastroenterology 95 (1988) 1435-1436
56. Schnoll-Sussman F., and Kurtz R.C. Gastrointestinal emergencies in the critically ill cancer patient. Semin Oncol 27 (2000) 270-283
57. Avigan D., Richardson P., Elias A., et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer 83 (1998) 409-414
58. Wade D.S., Nava H.R., and Douglass Jr. H.O. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 1 (1992) 17-23
59. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35